nach oben

Pathology & Oncology Research

Erschienen in:

01.03.2010

Expression and Methylation Pattern of p16 in Neuroblastoma Tumorigenesis

verfasst von: Safiye Aktas, Aydan Cavusoglu Celebiler, Zeynep Zadeoğluları, Gulden Diniz, Aydanur Kargı, Nur Olgun

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Understanding migration, population and differentiation of primordial neural crest cells will help in evolving biology of neuroblastoma. P16 is a tumour suppressor gene contributing in cell cycle arrest as cyclin dependent kinase inhibitor. Methylation is an important mechanism for silencing tumor suppressor genes. The aim of this study was to evaluate the role of p16 and its methylation pattern in neuroblastoma tumorigenesis. This study included 23 cases (11 male; 12 female) and 31 samples from archival paraffin embedded tissues. P16 was studied in 5 samples of normal adrenal medullar tissue, 5 samples of adrenal tissue including blastic rests, 5 samples of neuroblastoma in situ tissue and in 8 samples of neuroblastoma tissues primary and after chemotherapy in each group. The adrenal gland tissues were obtained from paediatric autopsy cases. Expression of p16 was searched by immunohistochemistry. Methylation specific PCR was used to detect the methylation rate of p16. The age range of autopsy cases was between 20 weeks of foetal age and 36 months of infant age. The mean age of neuroblastoma cases was 45 months. P16 expression was positive in normal adrenal tissues, in one of 5 samples of adrenal blastic rest tissue and in all of samples of after chemotherapy; while no expression was observed in neuroblastoma and neuroblastoma in situ tissues. P16 methylation was observed in samples of neuroblastoma in situ and primary neuroblastoma tissues. Our results suggest that p16 and its methylation seems to play role in neuroblastoma tumorigenesis and in the migration, population and differentiation of primordial neural crest cells. Inhibitors of DNA methylation may provide a useful tool for restoring p16 activity in neuroblastoma treatment.

Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC (2008) Methylation of tumor-suppressor genes in neuroblastoma: the RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 50(1):29–32CrossRefPubMed

Bassi CL, Martelli L, Cipolotti R, Scrideli CA, Defávery R, Tone LG (2004) Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients. Braz J Med Biol Res 37(11):1683–1687CrossRefPubMed

Takita J, Hayashi Y, Nakajima T, Adachi J, Tanaka T, Yamaguchi N, Ogawa Y, Hanada R, Yamamoto K, Yokota J (1998) The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 17(24):3137–3143CrossRefPubMed

Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL (2001) p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7(11):3481–3490PubMed

Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22(16):4212–4222CrossRefPubMed

Ohtani N, Yamakoshi K, Takahashi A, Hara E (2004) The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 51(3–4):146–153CrossRefPubMed

Ebinger M, Senf L, Wachowski O, Scheurlen W (2004) Promoter methylation pattern of caspase-8, P16INK4A, MGMT, TIMP-3, and E-cadherin in medulloblastoma. Pathol Oncol Res 10(1):17–21CrossRefPubMed

Ivanova TA, Golovina DA, Zavalishina LE, Volgareva GM, Katargin AN, Andreeva YY, Frank GA, Kisseljov FL (2007) Kisseljova NP.Up-regulation of expression and lack of 5′ CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas. BMC Cancer 7:47CrossRefPubMed

Attri J, Srinivasan R, Majumdar S, Radotra BD, Wig J (2005) Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol 5:22CrossRefPubMed

10.

Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P (2006) Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8(1):46–51CrossRefPubMed

11.

Conrad RM, Askin FB, Dehner LP (2001) Adrenal glands In: Dehner LP, Stocker JT (eds) Pediatric pathology, 2nd edn, vol 2. Lippincott Williams and Wilkins, pp 1040–1093

12.

Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C (2007) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr virus positive and negative pediatric Hodgkin lymphoma. Lymphat Res Biol 5(3):175–182CrossRefPubMed

13.

Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, Tlsty TD (2003) Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63(7):1596–1601PubMed

14.

De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M, De Paepe A, Laureys G, Påhlman S, Speleman F (2006) Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 7(9):R84CrossRefPubMed

15.

Strieder V, Lutz W (2003) E2F proteins regulate MYCN expression in neuroblastomas. J Biol Chem 278(5):2983–2989CrossRefPubMed

16.

Gebauer S, Yu AL, Omura-Minamisawa M, Batova A, Diccianni MB (2004) Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma. Genes Chromosomes Cancer 41(4):297–308CrossRefPubMed

17.

18.

Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A, Yau P, Virtanen C, Winegarden N, Cheng J, Gingeras T, Petronis A (2006) Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res 34(2):528–542CrossRefPubMed

19.

Clément G, Benhattar J (2005) A methylation sensitive dot blot assay (MS-DBA) for the quantitative analysis of DNA methylation in clinical samples. J Clin Pathol 58(2):155–158CrossRefPubMed

20.

Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG (1999) In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 96(22):12754–12759CrossRefPubMed

Titel: Expression and Methylation Pattern of p16 in Neuroblastoma Tumorigenesis
verfasst von: Safiye Aktas
Aydan Cavusoglu Celebiler
Zeynep Zadeoğluları
Gulden Diniz
Aydanur Kargı
Nur Olgun
Publikationsdatum: 01.03.2010
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 1/2010
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-009-9178-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Expression and Methylation Pattern of p16 in Neuroblastoma Tumorigenesis

Abstract

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

PPI-Delayed Diagnosis of Gastrinoma: Oncologic Victim of Pharmacologic Success

Chromosomal Integration of the HHV-6 Genome as a Possible Cause of Persistent HHV-6 Detection in a Patient with Langerhans Cell Histiocytosis

A Case of Primary Histiocytic Sarcoma Arising from Thyroid Gland

Ependymoma in Adults: Surgery, Reoperation and Radiotherapy for Survival

Expression of Matrix Metalloproteinase 2 and Extracellular Matrix Metalloproteinase Inducer are Unfavorable Postoperative Prognostic Factors in Intrahepatic Cholangiocarcinoma

Primary Large Cell Neuroendocrine Carcinoma of the Kidney

Neu im Fachgebiet Onkologie

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Update Onkologie